Press release 30 Apr 2015

Pour une approche intégrée contre les faux médicaments

Professionnels des affaires règlementaires, représentants des autorités de réglementation ou de la société civile et autres professionnels impliqués dans la lutte contre les faux médicaments se réunissent à Dakar dans le cadre d’un séminaire pour discuter d’ une approche intégrée contre les faux médicaments. Dakar (Sénégal) – Un séminaire sur la problématique des faux médicaments...

Read more
Press release 29 Apr 2015

New research-based pharmaceutical industry report provides insights on how to slow down antimicrobial resistance (AMR) and boost antibiotic R&D

• Report produced by leading R&D based pharmaceutical companies calls for a coherent, comprehensive and integrated approach at global and national levels to minimize growth of resistance to antibiotics. Preventing resistance requires a joint approach from healthcare professionals, pharmaceutical industry, policy makers and individual citizens to work together to promote appropriate antibiotic use. • Report...

Read more
Video 29 Apr 2015

Radio France Internationale – La lutte contre les faux médicaments

Click here to listen to the full interview

Read more
Statement 29 Apr 2015

LDCs request for extension of TRIPS implementation

IFPMA firmly supports the efforts of governments and civil society to increase access to medicines in developing countries, particularly in LDCs. Ensuring the availability, accessibility, and affordability of medicines is complex, and must be viewed within the overall context of universal health coverage. The vast majority of essential medicines are not protected by intellectual property...

Read more
Infographic 28 Apr 2015

IFPMA members’ antibacterial compounds pipeline inventory 2015

Read more
Infographic 28 Apr 2015

7 Recommendations for a new economic model to incentivize innovation, meet preservation goals and ensure access to antibiotics

Read more
Press release 27 Apr 2015

L’Afrique a besoin de systèmes réglementaires plus efficaces afin d’améliorer l’accès aux médicaments

Plus de 150 experts réglementaires de quelques 40 différents pays se réunissent à Dakar, Sénégal. Ils représentent, entre autres, des agences gouvernementales, des organisations multilatérales, l’industrie pharmaceutique, et la société civile pour discuter des moyens permettant d’accélérer la disponibilité des médicaments et vaccins pour les patients en Afrique. Dakar, 27-28 avril 2015 – DIA (Développer,...

Read more
Video 27 Apr 2015

IFPMA: Biotherapeutic medicines explained (Slovenian)

This IFPMA video illustrates what biotherapeutics are all about. They are typically derived from living organisms and are made by genetically engineering DNA. A high level of precision is required in the commercial manufacturing process to produce a consistent product each time. Every step we take in the production of these medicines requires highly controlled...

Read more
Infographic 24 Apr 2015

Counterfeit medicines in legitimate supply chains SDCP &PSI Study

Analysis of reports over a five year period – from 2005 to 2010 – indicates that counterfeit medicines increased by 122% while diversion and theft increased by 66%. Improvements in surveillance, including detection of security breaches, data collection, analysis, and dissemination are urgently needed to address the public health need to combat the global counterfeit...

Read more
Press release 24 Apr 2015

IFPMA pharma’s commitment to global vaccine action plan and to ‘closing the immunization gap’

Geneva, 24 April 2015 −A report entitled Innovation for a healthier world – how the research-based vaccine manufacturers are contributing to the Decade of Vaccines Global Vaccine Action Plan (GVAP) shows how the pharmaceutical industry is bringing innovation to close the immunization gap while stressing the importance of reaching the 20% of children who are...

Read more
Infographic 23 Apr 2015

R&D pipeline for malaria

Read more
Video 23 Apr 2015

IFPMA: Biotherapeutic medicines explained (Arabic)

This IFPMA video illustrates what biotherapeutics are all about. They are typically derived from living organisms and are made by genetically engineering DNA. A high level of precision is required in the commercial manufacturing process to produce a consistent product each time. Every step we take in the production of these medicines requires highly controlled...

Read more